הלוואות ואשראי לטווח ארוך של החברה: Avadel Pharma (AVDL)

Serving as the primary valuation tool, this Avadel Pharmaceuticals (AVDL) price chart demonstrates the company's dynamics, where a steady inflow of funds is driven by the medical community's habit of prescribing a high-demand narcolepsy treatment. The biopharmaceutical business relies on the successful rollout of Lumryz, patent litigation victories, and the treatment of rare pathologies, while the indicator stands at 0.03. Growth prospects are based on expansion into the pediatric sector and the achievement of a positive financial result.

This indicator measures total liabilities with a maturity of more than one year, determining the financial stability and the degree of the business's dependence on external borrowings. By analyzing the long-term debt capital trend, an investor assesses the ability of Avadel Pharmaceuticals (AVDL) to fund the expansion of Lumryz and cover operating expenses until target margins and insurance market coverage are achieved.